AR Signaling and the PI3K Pathway in Prostate Cancer

被引：145

作者：

Crumbaker, Megan ^{[1
,2
]}

Khoja, Leila ^{[3
,4
]}

Joshua, Anthony M. ^{[1
,2
,5
]}

机构：

[1] St Vincents Hosp, Kinghorn Canc Ctr, 370 Victoria St, Sydney, NSW 2010, Australia

[2] Univ New South Wales, St Vincents Clin Sch, Garvan Inst Med Res, 384 Victoria St, Sydney, NSW 2010, Australia

[3] AstraZeneca UK, Clin Discovery Unit, Early Clin Dev Innovat Med, da Vinci Bldg,Melbourn Sci Pk, Melbourn SG8 6HB, Herts, England

[4] Cambridge Univ Hosp NHS Fdn Trust, Addenbrookes Hosp, Cambridge Biomed Campus,Hills Rd, Cambridge CB2 0QQ, England

[5] Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Univ Ave, Toronto, ON M5G 2M9, Canada

来源：

CANCERS | 2017年 / 9卷 / 04期

关键词：

PI3K; prostate cancer; AR signaling; castrate resistant prostate cancer; ANDROGEN RECEPTOR VARIANTS; PHASE-II TRIAL; TUMOR-SUPPRESSOR; ABIRATERONE ACETATE; INCREASED SURVIVAL; CATALYTIC SUBUNIT; GROWTH-INHIBITION; SPLICE VARIANTS; DOSE-ESCALATION; PATIENTS PTS;

D O I：

10.3390/cancers9040034

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Prostate cancer is a leading cause of cancer-related death in men worldwide. Aberrant signaling in the androgen pathway is critical in the development and progression of prostate cancer. Despite ongoing reliance on androgen receptor (AR) signaling in castrate resistant disease, in addition to the development of potent androgen targeting drugs, patients invariably develop treatment resistance. Interactions between the AR and PI3K pathways may be a mechanism of treatment resistance and inhibitors of this pathway have been developed with variable success. Herein we outline the role of the PI3K pathway in prostate cancer and, in particular, its association with androgen receptor signaling in the pathogenesis and evolution of prostate cancer, as well as a review of the clinical utility of PI3K targeting.

引用

页数：15

共 107 条

[51]

Li BY, 2014, AM J CLIN EXP UROL, V2, P188

[52] Complex Impacts of PI3K/AKT Inhibitors to Androgen Receptor Gene Expression in Prostate Cancer Cells [J].

Liu, Liangliang ;

Dong, Xuesen .

PLOS ONE, 2014, 9 (10)

[53]

LoRusso P.M., 2016, J CLIN ONCOL

[54] Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation [J].

Mahajan, Nupam P. ;

Liu, Yuanbo ;

Majumder, Samarpan ;

Warren, Maria R. ;

Parker, Carol E. ;

Mohler, James L. ;

Earp, H. Shelton ;

Whang, Young E. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (20) :8438-8443

[55] The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis [J].

Massie, Charles E. ;

Lynch, Andy ;

Ramos-Montoya, Antonio ;

Boren, Joan ;

Stark, Rory ;

Fazli, Ladan ;

Warren, Anne ;

Scott, Helen ;

Madhu, Basetti ;

Sharma, Naomi ;

Bon, Helene ;

Zecchini, Vinny ;

Smith, Donna-Michelle ;

DeNicola, Gina M. ;

Mathews, Nik ;

Osborne, Michelle ;

Hadfield, James ;

MacArthur, Stewart ;

Adryan, Boris ;

Lyons, Scott K. ;

Brindle, Kevin M. ;

Griffiths, John ;

Gleave, Martin E. ;

Rennie, Paul S. ;

Neal, David E. ;

Mills, Ian G. .

EMBO JOURNAL, 2011, 30 (13) :2719-2733

[56] HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability [J].

Mellinghoff, IK ;

Vivanco, I ;

Kwon, A ;

Tran, C ;

Wongvipat, J ;

Sawyers, CL .

CANCER CELL, 2004, 6 (05) :517-527

[57] Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth [J].

Montgomery, R. Bruce ;

Mostaghel, Elahe A. ;

Vessella, Robert ;

Hess, David L. ;

Kalhorn, Thomas F. ;

Higano, Celestia S. ;

True, Lawrence D. ;

Nelson, Peter S. .

CANCER RESEARCH, 2008, 68 (11) :4447-4454

[58] Cell Autonomous Role of PTEN in Regulating Castration-Resistant Prostate Cancer Growth [J].

Mulholland, David J. ;

Tran, Linh M. ;

Li, Yunfeng ;

Cai, Houjian ;

Morim, Ashkan ;

Wang, Shunyou ;

Plaisier, Seema ;

Garraway, Isla P. ;

Huang, Jiaoti ;

Graeber, Thomas G. ;

Wu, Hong .

CANCER CELL, 2011, 19 (06) :792-804

[59] Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer [J].

Nakabayashi, Mari ;

Werner, Lilian ;

Courtney, Kevin D. ;

Buckle, Geoffrey ;

Oh, William K. ;

Bubley, Glen J. ;

Hayes, Julia H. ;

Weckstein, Douglas ;

Elfiky, Aymen ;

Sims, Danny M. ;

Kantoff, Philip W. ;

Taplin, Mary-Ellen .

BJU INTERNATIONAL, 2012, 110 (11) :1729-1735

[60] Androgen Receptor Splice Variants in the Era of Enzalutamide and Abiraterone [J].

Nakazawa, Mary ;

Antonarakis, Emmanuel S. ;

Luo, Jun .

HORMONES & CANCER, 2014, 5 (05) :265-273

← 1 2 3 4 5 6 7 8 9 10 →